Novartis (NVSN) Stock Price & Analysis
NVSN Stock Chart & Stats
- Day’s Range
- MXN 2,911.00 - MXN 3,138.99
- 52-Week Range
- MXN 2,180.41 - MXN 3,138.99
- Previous Close
- MXN 2,911.00
- Volume
- 38
- Average Volume (3M)
- 48
- Market Cap
- MXN 5.58T
- Enterprise Value
- MXN 311.27B
- Total Cash (Recent Filing)
- MXN 8.97B
- Total Debt (Recent Filing)
- MXN 48.31B
- Price to Earnings (P/E)
- 31.2
- Beta
- 0.30
- Next Earnings
- Feb 03, 2027 (Est.)
- EPS Estimate
- 41.8
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.97%
Bulls Say, Bears Say
Bulls Say
Growth Portfolio Momentum
Strong growth across multiple priority brands shows that Novartis has several commercially advancing products rather than relying on one medicine. Broad momentum across oncology, immunology, neuroscience and cardiovascular therapies supports durable revenue replacement as older products face erosion.
High-margin Operating Model
The combination of core profit growth, a 41.6% margin and lower SG&A indicates meaningful operating leverage in the business. Continued productivity can help fund research and launches while preserving profitability as Novartis expands its innovation portfolio.
Robust Cash Generation
Large free-cash-flow generation gives Novartis internal funding for clinical development, business development, dividends and repurchases. This financial capacity strengthens the company’s ability to sustain investment in new medicines through normal pipeline volatility.
Bears Say
Higher Financial Leverage
The sharp increase in debt relative to equity reduces balance-sheet flexibility and makes the company more sensitive to earnings volatility and financing costs. Higher leverage can constrain capital allocation if pipeline spending or commercial performance weakens.
Patent And Competitive Erosion
Generic and biosimilar competition can structurally reduce sales and profitability when exclusivity expires, requiring new launches to replace lost revenue. Entresto and Xolair pressure therefore creates an ongoing offset to growth and complicates margin expansion.
Pipeline Execution Setbacks
Multiple late-stage setbacks increase uncertainty around the pipeline’s ability to replenish future growth and reduce the return on prior development investment. The Rhapsido pause also delays a potential expansion, while failed trials can raise future R&D demands.
Novartis News
NVSN FAQ
What was Novartis’s price range in the past 12 months?
What is Novartis’s market cap?
When is Novartis’s upcoming earnings report date?
How were Novartis’s earnings last quarter?
Is Novartis overvalued?
Does Novartis pay dividends?
What is Novartis’s EPS estimate?
How many shares outstanding does Novartis have?
What happened to Novartis’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Novartis?
What is the TipRanks Smart Score and how is it calculated?
Novartis Stock Smart Score
Company Description
Novartis
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Vasant Narasimhan
- Employees
- 75,267
- Website
- www.novartis.com
- Address
- Lichtstrasse 35, Basel, BS, 4056, CH
Novartis (NVSN) Earnings & Revenues
NVSN Company Deck
NVSN Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, supported by 4% quarterly sales growth, 10% core operating income growth, 29% priority-brand growth, strong performance from key brands, positive remibrutinib data, multiple regulatory milestones and an upgrade to full-year core operating income guidance. However, reported earnings and nine-month results were weaker, while delgociptacine and pelacarsen had unsuccessful Phase 3 outcomes, Rhapsido autoimmune studies remain on hold, and generic and biosimilar pressures are expected to affect future performance. Highlights significantly outweighed the explicitly stated challenges.
View all MX:NVSN earnings summariesNVSN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 4 | 3 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 12 | 0 | 0 |